Monday, April 15, 2024 10:40:44 AM
As far as the timing of everything, I’m just speculating as I see it, and could be wrong, so we will have to see how it plays out. I do think many investors here don’t fully understand or appreciate how difficult it is for a small company like Northwest Bio to bring a novel cell therapy treatment to market, and be required to pioneer and orchestrate so many moving parts, especially with contractors and backlogged regulators. It’s far easier to sit in the back seat (with a very limited view) and point fingers at the wouldas and couldas along the way. (I’m not saying that you’re doing this meirluc)
I keep hearing this same line repeated - that all these cancer patients are dying because it is taking so long to bring this treatment to market, and somehow, that is seen as Northwest Bio’s fault. Let’s get something straight: The length of time it has taken is not all Northwest Bio’s fault. And neither is all the dilution that resulted from the short attack, and being forced to raise capital at prices well below $1, with warrants and other unfavorable terms attached.
Remember that Northwest Bio was on track with multiple clinical trials for both DCVax-L and Direct, attending investor conferences, trading on the Nasdaq, receiving investment from institutional investors, before it was attacked, frivolous lawsuits brought against them, and a false narrative created and spread, to make to appear as if “DCVax doesn’t work, the phase III trial failed, and management is misleading investors.”
The fact is, that Northwest Bio’s stock had risen rapidly to a high of over $12 which gained the attention of nefarious hedge funds, who saw an opportunity to make some easy, risk-free money. They hired someone to write a false “research report” as a basis for them to perpetrate a short and distort attack on the stock. These hedge funds are the ones responsible for starving Northwest Bio of the necessary resources required to bring DCVax to market in a timely manner, and depriving cancer patients of this treatment.
Linda Powers and Northwest Bio have survived the attack and overcome numerous hurdles in their path to bringing this novel cell therapy to the commercial market. They have almost solved the major bottlenecks that would prevent the large scale manufacturing and mass distribution of this cell therapy, and are now finally on the verge of regulatory approval. I have full confidence that when the time comes for commercial manufacturing, the best choice will be made, whatever that is.
Recent NWBO News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM
HealthLynked Corp Announces First Quarter 2024 Results: Achieves 8% Revenue Growth Over Last Quarter • HLYK • May 16, 2024 8:00 AM
Integrated Ventures Files Q3/2024 With Mining Revenues Of $1,983,250 And Positive Earnings Of $0.05 Cents Per Share • INTV • May 15, 2024 10:30 AM